Form 4 for JANX Janux Therapeutics, Inc.
Accepted 2025-10-30 00:00:00 ET · period of report 2025-10-28 · accession 0001864159-25-000003 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-10-30 | 2025-10-28 | JANX | Meyer Andrew Hollman | Chief Business Off | S - Sale+OE | $30.06 | -16.7K | 82.1K | -17% | -$500.9K |
| DM | 2025-10-30 | 2025-10-28 | JANX | Meyer Andrew Hollman | Chief Business Off | M - OptEx | $6.76 | +16.7K | 98.8K | +20% | +$112.7K |
| DM | 2025-10-30 | 2025-10-28 | JANX | Meyer Andrew Hollman | Chief Business Off | M - OptEx | $0.00 | -16.7K | 77.3K | -18% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-10-28 | S | D | 16,665 | $30.06 | 82,139 | D | — | — | (F2) The weighted average sale price for the transaction reported was $30.0622 and the range of prices were between $30.00 and $30.49. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| 2 | Common | Common Stock | 2025-10-28 | M | A | 9,999 | $4.21 | 92,138 | D | — | — | |
| 3 | Common | Common Stock | 2025-10-28 | M | A | 6,666 | $10.59 | 98,804 | D | — | — | |
| 4 | Derivative | Stock Option (right to buy) | 2025-10-28 | M | D | 6,666 | $0.00 | 121,434 | D | $10.59 · — to 2031-05-13 | 6,666 Common Stock | (F3) Immediately exercisable. |
| 5 | Derivative | Stock Option (right to buy) | 2025-10-28 | M | D | 9,999 | $0.00 | 77,333 | D | $4.21 · — to 2031-03-09 | 9,999 Common Stock | (F3) Immediately exercisable. |